Federica Zilli
University Hospital of Basel
2 Papers
Federica Zilli is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 1, co-authored 1 publications. Previous affiliations of Federica Zilli include Friedrich Miescher Institute for Biomedical Research.
Chat about Author
Papers
The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells.
Federica Zilli,Federica Zilli,Pedro Marques Ramos,Pedro Marques Ramos,Priska Auf der Maur,Charly Jehanno,Atul Sethi,Atul Sethi,Atul Sethi,Marie-May Coissieux,Marie-May Coissieux,Tobias Eichlisberger,Loïc Sauteur,Adelin Rouchon,Laura Bonapace,Joana Pinto Couto,Joana Pinto Couto,Joana Pinto Couto,Roland Rad,Roland Rad,Michael Rugaard Jensen,Andrea Banfi,Michael B. Stadler,Michael B. Stadler,Mohamed Bentires-Alj,Mohamed Bentires-Alj +25 more
TL;DR: In this article, an inducible piggyBac transposon mutagenesis screen was used to show that NFIB alone is sufficient to enhance primary mammary tumour growth and lung metastatic colonization.
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer
P. Auf der Maur,Marcel P. Trefny,Zora Baumann,Milica Vulin,Ana Luísa Correia,Maren Diepenbruck,Katrin Volkmann,Bogdan-Tiberius Preca,P Ramos,Cédric Leroy,Tobias Eichlisberger,Katarzyna Buczak,Federica Zilli,Ryoko Okamoto,Roland Rad,Michael Rugaard Jensen,Christine Fritsch,Alfred Zippelius,Michael B. Stadler,Mohamed Bentires-Alj +19 more
TL;DR: In this paper , a genome-wide PiggyBac transposon-mediated screen and a resistance screen in a PIK3CAH1047R-mutated murine tumor model reveal NF1 loss in mammary tumors resistant to the phosphatidylinositol 3kinase α (PI3Kα)-selective inhibitor alpelisib.
8